CAM
TEVA icon

Cypress Asset Management’s Teva Pharmaceuticals TEVA Stock Holding History

Cypress Asset Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-6,240
Closed -$226K – 212
2016
Q4 		$226K Sell
6,240
-400
-6% -$16K 0.04% 198
2016
Q3 		$306K Sell
6,640
-200
-3% -$10.4K 0.06% 169
2016
Q2 		$344K Hold
6,840
– – 0.07% 158
2016
Q1 		$366K Sell
6,840
-810
-11% -$47.5K 0.07% 154
2015
Q4 		$502K Sell
7,650
-125
-2% -$7.72K 0.1% 134
2015
Q3 		$439K Hold
7,775
– – 0.09% 137
2015
Q2 		$460K Buy
7,775
+150
+2% +$9.25K 0.09% 143
2015
Q1 		$475K Buy
7,625
+75
+1% +$4.36K 0.09% 137
2014
Q4 		$434K Buy
7,550
+200
+3% +$11.1K 0.08% 149
2014
Q3 		$395K Sell
7,350
-100
-1% -$5.3K 0.07% 155
2014
Q2 		$391K Hold
7,450
– – 0.07% 160
2014
Q1 		$394K Hold
7,450
– – 0.07% 151
2013
Q4 		$299K Sell
7,450
-200
-3% -$7.88K 0.05% 164
2013
Q3 		$289K Sell
7,650
-14,375
-65% -$561K 0.05% 158
2013
Q2 		$863K Buy
+22,025
New +$858K 0.16% 108

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Cypress Asset Management's TEVA Position: Q1 2017 in Review

Cypress Asset Management sold out of Teva Pharmaceuticals (TEVA) in Q1 2017, closing a stake of 6,240 shares — an estimated $226K sold.

Cypress Asset Management first reported a position in TEVA in Q2 2013 and held it in 15 quarters. The position peaked at $863K in Q2 2013. 686 funds tracked by Wall St. Rank hold TEVA as of Q1 2017.

  • Cypress Asset Management reported no remaining Teva Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Cypress Asset Management sold 6,240 Teva Pharmaceuticals shares in Q1 2017, an estimated $226K.
  • Cypress Asset Management first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 15 quarters.
  • Cypress Asset Management's Teva Pharmaceuticals position peaked at $863K in Q2 2013.
  • 686 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2017.

Based on Cypress Asset Management's 13F filing for Q1 2017, filed 12 May 2017.